Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents

Transplantation

Volumn 101, Issue 7, 2017, Pages 1704-1710

  Lubetzky, Michelle ^a   Chun, Soohwan ^a   Joelson, Andrew ^a   Coco, Maria ^a   Kamal, Layla ^a   Ajaimy, Maria ^a   Gaglio, Paul ^b   Akalin, Enver ^a   De Boccardo, Graciella ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; LOSARTAN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; MALE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; VIRUS DETECTION; VIRUS LOAD; ADVERSE EFFECTS; ALLOGRAFT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; GRAFT SURVIVAL; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ALLOGRAFTS; ANTIVIRAL AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85007232631     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001618     Document Type: Article

References (16)

1. Holmberg SD, Spradling PR, Moorman AC, et al. Hepatitis C in the United States. N Engl JMed. 2013;368:1859-1861.
2. Baid-Agrawal S, PascualM,Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol. 2008;18: 97-115.
3. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21: 314-324.
4. Rostami Z, NourbalaMH, Alavian SM, et al. The impact of Hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon. 2011;11:247-254.
5. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370: 222-232.
6. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370: 1483-1493.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl JMed. 2014;370:1889-1898.
8. Kwo PY, Tector AJ. Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis. Liver Transpl. 2013;19:780-781.
9. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108-117.
10. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823-830.
11. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61:1880-1886.
12. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013;19: 690-700.
13. Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.
14. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.
15. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.
16. Guidelines HCV. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection. Updated 2016. Accessed November 2016.